Platinum-Resistant Ovarian CancerPhase 1NCT06964009
DT2216
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Combination Therapy for Recurrent Ovarian Cancer
What the film says
This trial is for adults with recurrent ovarian cancer for whom liposomal doxorubicin is a treatment option.
The idea: add ashwagandha, a plant extract containing withaferin A, taken as tablets by mouth, to the chemotherapy liposomal doxorubicin, given by vein every four weeks. The first part tests three ashwagandha doses.
This phase 1 and 2 study plans 72 patients and looks at feasibility, the maximum tolerated dose and progression free survival. At the University of Louisville's Brown Cancer Center, Whitney Goldsberry leads it.
Public record; not medical advice.
Sources behind this film
Adults; recurrent ovarian cancer, liposomal doxorubicin acceptable; Ashwagandha tablets by mouth (withaferin A) with DOXIL IV every four weeks; First part tests three ashwagandha doses; Phase 1/2; 72 patients; feasibility, MTD, PFS (+1 more lines)
The drug
Ashwagandha in the form of tablets will be administered orally on daily basis.
Administered orally on daily basis twice a day
Study Design Overview: This is a two-part open-label clinical trial of ASWD (Ashwagandha) administered to patients with recurrent ovarian cancer in combination with liposomal doxorubicin, (DOXIL) following at least one previous line of chemotherapy. Patients will initially be enrolled in part 1 of the study, which is the feasibility/tolerability evaluation. Once the part 1 enrollment is completed, the patients will be enrolled in part 2 of the study.
The study
The proposed study "combination therapy with liposomal doxorubicin and withaferin A (Ashwagandha, ASWD) in recurrent ovarian cancer" is focused to determine the feasibility and maximum tolerance dose of Ashwagandha with liposomal doxorubicin (DOXIL) in recurrent ovarian cancer patients. The study contains two parts.
In part 1 (phase I), 18 patients with recurrent ovarian cancer eligible for DOXIL therapy will be recruited and three doses of Ashwagandha (2.0 g, 4.0 g and 8.0 g) in the form of tablets along with DOXIL will be evaluated for feasibility and tolerance of ASWD.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.